Atea Pharmaceuticals
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company developing oral direct-acting antiviral therapies, with a lead HCV regimen (bemnifosbuvir plus ruzasvir) in global Phase 3 trials and an early-stage hepatitis E candidate, targeting patients with serious RNA viral infections.
- Company typePublic
- Founded2014
- HeadquartersBoston, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Atea Pharmaceuticals does
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, that discovers and develops oral direct-acting antiviral therapies targeting single-stranded RNA viruses, with current pipeline focus on hepatitis C (HCV) and hepatitis E (HEV). Its core technology is a proprietary purine nucleos(t)ide prodrug platform designed to inhibit viral RNA-dependent RNA polymerase; lead assets include the nucleotide analog polymerase inhibitor bemnifosbuvir (AT-511) and the NS5A inhibitor ruzasvir, formulated as a once-daily, protease-inhibitor-free fixed-dose combination for HCV, plus the investigational HEV candidate AT-587.
The company's technology differentiators include approximately 10-fold greater in vitro potency than sofosbuvir against HCV GT1-5, full activity against S282T resistance-associated substitutions, an 8-week treatment duration for non-cirrhotic patients, no food effect, and low drug-drug interaction risk with common co-medications. Bemnifosbuvir has been administered to over 2,300 subjects and ruzasvir to over 2,100 HCV-infected patients in trials to date. The platform is currently in global Phase 3 development, with the C-BEYOND (North America) and C-FORWARD (17 countries outside North America) trials each having enrolled over 880 patients, and topline data from C-FORWARD expected around year-end 2026.
Atea is pre-revenue with no approved products on the market; the company reported an annual net loss of $158.35 million against approximately $256 million in cash as of Q1 2026, providing runway through 2027. Capital has historically come from a $215 million Series D (May 2020, led by Bain Capital Life Sciences) and a $350 million upfront payment from a 2020 strategic collaboration with Roche for ex-U.S. rights to AT-527 in COVID-19. Future revenue is planned from commercialization of the bemnifosbuvir/ruzasvir regimen targeting the ~$2.5 billion global HCV therapeutics market, with leadership now being expanded via a Chief Commercial Officer to support an enterprise sales motion into healthcare-provider networks.
Atea Pharmaceuticals firmographics
Firmographics- Name
- Atea Pharmaceuticals
- Legal name
- Atea Pharmaceuticals, Inc.
- Website
- https://ateapharma.com
- Company type
- Public
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Atea Pharmaceuticals is a clinical-stage biopharmaceutical company developing oral direct-acting antiviral therapies, with a lead HCV regimen (bemnifosbuvir plus ruzasvir) in global Phase 3 trials and an early-stage hepatitis E candidate, targeting patients with serious RNA viral infections.
- Ownership category
- akta.pro rank
Atea Pharmaceuticals industry classification
Industry- Product category
- Antiviral Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC)
- akta.pro secondary industries
- Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG), Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)
Keywords
Where Atea Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Markets served
Atea Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Pre-revenue clinical-stage operations: Atea is currently a clinical-stage biopharmaceutical company with no commercial product revenue; reported an annual loss of $158.35 million and has not yet launched a product. Capital is sourced from equity financings (e.g., $215M Series D in 2020) and existing cash reserves of $256 million (Q1 2026) supporting runway through 2027.
- Future product sales (planned HCV regimen commercialization): Future revenue expected from commercialization of bemnifosbuvir + ruzasvir fixed-dose combination for HCV, targeting a market with approximately $2.5 billion in 2025 global net sales (Mavyret/Epclusa and authorized generic).
- Licensing royalties (historical Roche collaboration): Under the October 2020 strategic collaboration with Roche for AT-527 (COVID-19), Atea received a $350 million upfront cash payment with the potential for future milestone payments and royalties on sales of AT-527 outside the United States.
Go-to-market motion2 records
Atea Pharmaceuticals product offering
Product offeringCore offering
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company developing oral direct-acting antiviral therapeutics for severe human viral infections, anchored by a proprietary purine nucleos(t)ide prodrug platform. Its lead program is a once-daily, fixed-dose combination regimen of bemnifosbuvir (nucleotide analog polymerase inhibitor) and ruzasvir (NS5A inhibitor) in global Phase 3 development for hepatitis C virus (HCV), with the AT-587 candidate advancing as a potential first-in-class direct-acting antiviral for hepatitis E virus (HEV).
Differentiator
Problem solved
Functional benefit
Products and services
- Bemnifosbuvir + Ruzasvir Fixed-Dose Combination Regimen Oral once-daily, protease-inhibitor-free fixed-dose combination of bemnifosbuvir (nucleotide analog polymerase inhibitor) and ruzasvir (NS5A inhibitor) being developed for the treatment of chronic hepatitis C virus (HCV) infection. Designed for 8-week (treatment-naïve non-cirrhotic) or 12-week (compensated cirrhotic) durations with no food effect and low drug-drug interaction risk, including with PPIs and statins. Targeted at hepatologists, infectious disease specialists, and HCV treatment networks globally.
- AT-587 (Investigational HEV Direct-Acting Antiviral) Investigational oral direct-acting antiviral being developed by Atea for the treatment of hepatitis E virus (HEV) infection. AT-587 has demonstrated 30- to 150-fold higher in vitro potency against HEV compared to sofosbuvir and ribavirin. Targeted at hepatologists and infectious disease specialists managing HEV-infected patients, including immunocompromised populations where no approved DAA currently exists.
Companies that use Atea Pharmaceuticals
Customer profileIdeal customer profiles2 records
Atea Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature5 records
Atea Pharmaceuticals partnerships and signals
Strategic signalRecent moves6 records
Expansion highlights5 records
Atea Pharmaceuticals competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Atea Pharmaceuticals social profiles
Digital presenceAtea Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Atea Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles1 record
Atea Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds4 records
Investors14 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Atea Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Atea Pharmaceuticals
What does Atea Pharmaceuticals do?
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company developing oral direct-acting antiviral therapeutics for severe human viral infections, anchored by a proprietary purine nucleos(t)ide prodrug platform. Its lead program is a once-daily, fixed-dose combination regimen of bemnifosbuvir (nucleotide analog polymerase inhibitor) and ruzasvir (NS5A inhibitor) in global Phase 3 development for hepatitis C virus (HCV), with the AT-587 candidate advancing as a potential first-in-class direct-acting antiviral for hepatitis E virus (HEV).
Is Atea Pharmaceuticals a public or private company?
Atea Pharmaceuticals is a public company. It is classified as public and is currently operating.
When was Atea Pharmaceuticals founded?
Atea Pharmaceuticals was founded in 2014. It employs 51 to 100 people.
Where is Atea Pharmaceuticals based?
Atea Pharmaceuticals is headquartered in Boston, United States, in the North America region.
How does Atea Pharmaceuticals make money?
Three revenue lines are on record. Pre-revenue clinical-stage operations are the primary driver. The others are future product sales (planned HCV regimen commercialization) and licensing royalties (historical Roche collaboration).
Does Atea Pharmaceuticals have an API?
No public API is recorded for Atea Pharmaceuticals.
What industry is Atea Pharmaceuticals in?
Atea Pharmaceuticals's product category is Antiviral Pharmaceuticals. Its primary akta.pro industry code is HLAAAEAC, Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens), with a secondary code of HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.